

Maiwenn J Al

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2280906/publications.pdf>

Version: 2024-02-01

74
papers

3,143
citations

186209

28
h-index

161767

54
g-index

76
all docs

76
docs citations

76
times ranked

4581
citing authors

#	ARTICLE	IF	CITATIONS
1	Costs, effects and C/E-ratios alongside a clinical trial. <i>Health Economics (United Kingdom)</i> , 1994, 3, 309-319.	0.8	825
2	Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 353-360.e2.	1.5	263
3	Viscoelastic point-of-care testing to assist with the diagnosis, management and monitoring of haemostasis: a systematic review and cost-effectiveness analysis. <i>Health Technology Assessment</i> , 2015, 19, 1-228.	1.3	230
4	The analysis of incomplete cost data due to dropout. <i>Health Economics (United Kingdom)</i> , 2005, 14, 763-776.	0.8	88
5	Association between lung function and exacerbation frequency in patients with COPD. <i>International Journal of COPD</i> , 2010, 5, 435.	0.9	79
6	Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis. <i>Health Technology Assessment</i> , 2014, 18, 1-106.	1.3	74
7	The cost-utility of rotavirus vaccination with Rotarix [®] (RIX4414) in the Netherlands. <i>Vaccine</i> , 2008, 26, 1118-1127.	1.7	69
8	The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report. <i>Value in Health</i> , 2009, 12, 1086-1099.	0.1	69
9	Economic valuation of informal care: The conjoint measurement method applied to informal caregiving. <i>Social Science and Medicine</i> , 2005, 61, 1342-1355.	1.8	63
10	Faecal immunochemical tests to triage patients with lower abdominal symptoms for suspected colorectal cancer referrals in primary care: a systematic review and cost-effectiveness analysis. <i>Health Technology Assessment</i> , 2017, 21, 1-234.	1.3	59
11	Integrated sensor-augmented pump therapy systems [the MiniMed [®] Paradigm [™] , Veo system and the Vibe [™] and G4 [®] PLATINUM CGM (continuous glucose monitoring) system] for managing blood glucose levels in type 1 diabetes: a systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2016, 20, 1-252.	1.3	57
12	Methods to Analyse Cost Data of Patients Who Withdraw in a Clinical Trial Setting. <i>Pharmacoeconomics</i> , 2003, 21, 1103-1112.	1.7	54
13	Cost-utility of brief psychological treatment for depression and anxiety. <i>British Journal of Psychiatry</i> , 2006, 188, 323-329.	1.7	54
14	Cost-effectiveness of Lung Transplantation in the Netherlands. <i>Chest</i> , 1998, 113, 124-130.	0.4	52
15	Expected Value of Perfect Information: An Empirical Example of Reducing Decision Uncertainty by Conducting Additional Research. <i>Value in Health</i> , 2008, 11, 1070-1080.	0.1	52
16	<p>First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 1413-1421.	1.0	51
17	Sample size calculation in economic evaluations. , 1998, 7, 327-335.		47
18	Optimizing a portfolio of health care programs in the presence of uncertainty and constrained resources. <i>Social Science and Medicine</i> , 2003, 57, 2207-2215.	1.8	45

#	ARTICLE	IF	CITATIONS
19	Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme. <i>Cancer</i> , 2008, 112, 1337-1344.	2.0	44
20	Review of A Large Clinical Series: A Microcosting Study of Intensive Care Unit Stay in the Netherlands. <i>Journal of Intensive Care Medicine</i> , 2008, 23, 250-257.	1.3	38
21	Technology Assessment of the Dutch Lung Transplantation Program. <i>International Journal of Technology Assessment in Health Care</i> , 1998, 14, 344-356.	0.2	37
22	Healthcare Resource Utilisation and Costs of Treating NSAID-Associated Gastrointestinal Toxicity. <i>Pharmacoeconomics</i> , 2001, 19, 17-32.	1.7	34
23	Decision makers' views on health care objectives and budget constraints: results from a pilot study. <i>Health Policy</i> , 2004, 70, 33-48.	1.4	34
24	Economic Valuation of Informal Care: Conjoint Analysis Applied in a Heterogeneous Population of Informal Caregivers. <i>Value in Health</i> , 2008, 11, 1041-1050.	0.1	33
25	The Missing Stakeholder Group: Why Patients Should be Involved in Health Economic Modelling. <i>Applied Health Economics and Health Policy</i> , 2016, 14, 129-133.	1.0	33
26	TECH-VER: A Verification Checklist to Reduce Errors in Models and Improve Their Credibility. <i>Pharmacoeconomics</i> , 2019, 37, 1391-1408.	1.7	33
27	A Bayesian approach to economic analyses of clinical trials: the case of stenting versus balloon angioplasty. <i>Health Economics (United Kingdom)</i> , 2000, 9, 599-609.	0.8	31
28	Optimal allocation of resources over health care programmes: dealing with decreasing marginal utility and uncertainty. <i>Health Economics (United Kingdom)</i> , 2005, 14, 655-667.	0.8	31
29	Cost-consequence analysis of remifentanyl-based analgo-sedation vs. conventional analgesia and sedation for patients on mechanical ventilation in the Netherlands. <i>Critical Care</i> , 2010, 14, R195.	2.5	31
30	Developing and Applying a Stochastic Dynamic Population Model for Chronic Obstructive Pulmonary Disease. <i>Value in Health</i> , 2011, 14, 1039-1047.	0.1	30
31	Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations. <i>European Journal of Health Economics</i> , 2020, 21, 153-164.	1.4	30
32	Cost-Effectiveness Acceptability Curves Revisited. <i>Pharmacoeconomics</i> , 2013, 31, 93-100.	1.7	28
33	Comparison of cardiovascular risk algorithms in patients with <i>vs</i> without rheumatoid arthritis and the role of C-reactive protein in predicting cardiovascular outcomes in rheumatoid arthritis. <i>Rheumatology</i> , 2017, 56, 777-786.	0.9	28
34	Effects of Achieving Target Measures in Rheumatoid Arthritis on Functional Status, Quality of Life, and Resource Utilization: Analysis of Clinical Practice Data. <i>Arthritis Care and Research</i> , 2016, 68, 308-317.	1.5	27
35	Revisiting the decision rule of cost-effectiveness analysis under certainty and uncertainty. <i>Social Science and Medicine</i> , 2003, 57, 969-974.	1.8	26
36	Continuous versus Intermittent Data Collection of Health Care Utilization. <i>Medical Decision Making</i> , 2013, 33, 998-1008.	1.2	26

#	ARTICLE	IF	CITATIONS
37	The use of fenestrated and branched endovascular aneurysm repair for juxtarenal and thoracoabdominal aneurysms: a systematic review and cost-effectiveness analysis. <i>Health Technology Assessment</i> , 2014, 18, 1-66.	1.3	25
38	Cardiovascular risk factor management in patients with RA compared to matched non-RA patients. <i>Rheumatology</i> , 2016, 55, 809-816.	0.9	21
39	Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2017, 35, 1211-1221.	1.7	21
40	Use of Value of Information in Healthcare Decision Making: Exploring Multiple Perspectives. <i>Pharmacoeconomics</i> , 2016, 34, 315-322.	1.7	19
41	Costs and Effects of Various Analgesic Treatments for Patients with Rheumatoid Arthritis and Osteoarthritis in The Netherlands. <i>Value in Health</i> , 2008, 11, 589-599.	0.1	15
42	Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia. <i>Applied Health Economics and Health Policy</i> , 2019, 17, 883-893.	1.0	15
43	Uncertainty in Decision-Making: Value of Additional Information in the Cost-Effectiveness of Lifestyle Intervention in Overweight and Obese People. <i>Value in Health</i> , 2008, 11, 424-434.	0.1	14
44	Impact of hospitalisation on health-related quality of life in patients with chronic heart failure. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 262.	1.0	14
45	The Cost Effectiveness of Diclofenac Plus Misoprostol Compared with Diclofenac Monotherapy in Patients with Rheumatoid Arthritis. <i>Pharmacoeconomics</i> , 1996, 10, 141-151.	1.7	13
46	The cost utility of solifenacin in the treatment of overactive bladder. <i>International Urology and Nephrology</i> , 2009, 41, 293-298.	0.6	12
47	Avatrombopag and lusutrombopag for thrombocytopenia in people with chronic liver disease needing an elective procedure: a systematic review and cost-effectiveness analysis. <i>Health Technology Assessment</i> , 2020, 24, 1-220.	1.3	12
48	Portfolio theory and the alternative decision rule of cost-effectiveness analysis: theoretical and practical considerations. <i>Social Science and Medicine</i> , 2004, 58, 1853-1855.	1.8	10
49	A New Statistical Method to Determine the Degree of Validity of Health Economic Model Outcomes against Empirical Data. <i>Value in Health</i> , 2017, 20, 1041-1047.	0.1	10
50	Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2018, 36, 145-159.	1.7	10
51	Cost-effectiveness of tiotropium versus salmeterol: the POET-COPD trial. <i>European Respiratory Journal</i> , 2013, 41, 556-564.	3.1	9
52	The increasing importance of a continence nurse specialist to improve outcomes and save costs of urinary incontinence care: an analysis of future policy scenarios. <i>BMC Family Practice</i> , 2018, 19, 31.	2.9	9
53	Conceptual model for the health technology assessment of current and novel interventions in rheumatoid arthritis. <i>PLoS ONE</i> , 2018, 13, e0205013.	1.1	9
54	Quo Vadis HTA for Medical Devices in Central and Eastern Europe? Recommendations to Address Methodological Challenges. <i>Frontiers in Public Health</i> , 2020, 8, 612410.	1.3	9

#	ARTICLE	IF	CITATIONS
55	A Risk-Adjusted Approach to Comparing the Return on Investment in Health Care Programs. <i>International Journal of Health Care Finance and Economics</i> , 2004, 4, 199-210.	1.2	8
56	Comparing Methods of Data Synthesis. <i>Pharmacoeconomics</i> , 2011, 29, 239-250.	1.7	8
57	Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia in Ukraine. <i>Cancer Management and Research</i> , 2015, 7, 279.	0.9	8
58	Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2019, 37, 141-153.	1.7	8
59	The Role of Value-of-Information Analysis in a Health Care Research Priority Setting. <i>Medical Decision Making</i> , 2013, 33, 472-489.	1.2	7
60	Portfolio Theory and Cost-Effectiveness Analysis: A Further Discussion. <i>Value in Health</i> , 2004, 7, 595-601.	0.1	6
61	Economic evaluation alongside a single RCT of an integrative psychotherapeutic nursing home programme. <i>BMC Health Services Research</i> , 2013, 13, 370.	0.9	6
62	Model-based cost-effectiveness analyses comparing combinations of urate lowering therapy and anti-inflammatory treatment in gout patients. <i>PLoS ONE</i> , 2022, 17, e0261940.	1.1	6
63	Conclusion on cost-effectiveness of rotavirus vaccination highly dependent on assumptions. <i>Vaccine</i> , 2009, 27, 2531-2532.	1.7	5
64	A Choice That Matters?. <i>Pharmacoeconomics</i> , 2013, 31, 719-730.	1.7	5
65	Research Costs Investigated: A Study Into the Budgets of Dutch Publicly Funded Drug-Related Research. <i>Pharmacoeconomics</i> , 2018, 36, 105-113.	1.7	5
66	Determining the Impact of Modeling Additional Sources of Uncertainty in Value-of-Information Analysis. <i>Value in Health</i> , 2015, 18, 100-109.	0.1	4
67	Early warning systems for the management of chronic heart failure: a systematic literature review of cost-effectiveness models. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018, 18, 161-175.	0.7	4
68	Modeling Early Warning Systems: Construction and Validation of a Discrete Event Simulation Model for Heart Failure. <i>Value in Health</i> , 2021, 24, 1435-1445.	0.1	3
69	Inverse probability weighting to control for censoring in a post hoc analysis of quality-adjusted survival data from a clinical trial of temsirolimus for renal cell carcinoma. <i>Journal of Medical Economics</i> , 2011, 14, 245-252.	1.0	2
70	Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene. <i>Pharmacoeconomics</i> , 2016, 34, 23-31.	1.7	2
71	Cost Recommendation under Uncertainty in IQWiG's Efficiency Frontier Framework. <i>Medical Decision Making</i> , 2017, 37, 162-172.	1.2	2
72	Home Telemonitoring and a Diagnostic Algorithm in the Management of Heart Failure in the Netherlands: Cost-effectiveness Analysis. <i>JMIR Cardio</i> , 2022, 6, e31302.	0.7	1

#	ARTICLE	IF	CITATIONS
73	Mix and match. A simulation study on the impact of mixed-treatment comparison methods on health-economic outcomes. PLoS ONE, 2017, 12, e0171292.	1.1	0
74	Being Transparent About Brilliant Failures: An Attempt to Use Real-World Data in a Disease Model for Patients with Castration-Resistant Prostate Cancer. Drugs - Real World Outcomes, 2022, , 1.	0.7	0